Document and Entity Information - shares	9 Months Ended Jun. 30, 2016	Nov. 07, 2016
Document and Entity Information [Abstract]		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	0001112372	
Amendment Flag	false	
Current Fiscal Year End Date	--09-30	
Document Type	10-Q	
Document Period End Date	Jun. 30, 2016	
Document Fiscal Year Focus	2016	
Document Fiscal Period Focus	Q3	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		84,304,627

Consolidated Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Current Assets		
Cash and cash equivalents	$ 399,184	
Accounts receivable, net of allowance for bad debt of $2,700 at June 30, 2016		$ 57,031
Inventories	$ 247,375	210,579
Prepaid expenses	27,754	7,183
Total Current Assets	674,313	274,793
Property and Equipment		
Tooling and machinery	593,935	558,706
Furniture and office equipment	144,633	128,163
Leasehold improvements	24,158	22,871
Total property and equipment	762,726	709,740
Less accumulated depreciation	(668,936)	(578,738)
Total property and equipment, net	93,790	131,002
Other Assets		
Patents (net of accumulated amortization of $80,933 and $56,993)	64,915	53,041
Total assets	$ 833,018	458,836
Current Liabilities		
Bank line		$ 74,663
Deferred income	$ 10,622	
Accounts payable and accrued expenses	66,195	$ 109,712
Advance from related party	500,000	$ 30,000
Short term borrowings	300,000	
Current portion of long term debts	8,477	$ 35,795
Total Current Liabilities	885,294	250,170
Total Liabilities	$ 885,294	$ 250,170
Commitments		
Stockholders' Equity (Deficit)		
Preferred stock, $.0001 par value; 3,000,000 shares authorized; No issued and outstanding shares as of June 30, 2016 and September 30, 2015.		
Common stock, $.0001 par value; 100,000,000 shares authorized; 84,304,627 issued and outstanding as of June 30, 2016 and September 30, 2015	$ 8,430	$ 8,430
Additional paid-in capital	12,917,025	12,917,025
Accumulated deficit	(12,627,711)	(12,330,450)
Other comprehensive loss	(350,020)	(386,339)
Total Stockholders' Equity (Deficit)	(52,276)	208,666
Total Liabilities and Stockholders' Equity (Deficit)	$ 833,018	$ 458,836

Consolidated Balance Sheet (Parenthetical) (Unaudited) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Balance Sheet [Abstract]		
Accounts receivable, allowance for bad debt	$ 2,700	
Net of accumulated amortization	$ 80,933	$ 56,993
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	84,304,627	84,304,627
Common stock, shares outstanding	84,304,627	84,304,627

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statements of Operations [Abstract]				
Sales	$ 50,875	$ 140,945	$ 292,125	$ 439,249
Cost of sales	(69,133)	(39,864)	(144,413)	(121,703)
Gross profit (loss)	(18,258)	101,081	147,712	317,546
Selling, general, and administrative expenses	(151,403)	(91,057)	(442,091)	(258,896)
Total operating expenses	(151,403)	(91,057)	(442,091)	(258,896)
Profit (loss) from operations	(169,661)	10,024	(294,379)	58,650
Other Income (Expense)				
Interest income	105	188	497	687
Interest expense	(959)	(2,717)	(3,379)	(8,046)
Other income (expense), net	(854)	(2,529)	(2,882)	(7,359)
Net profit (loss)	$ (170,515)	$ 7,495	$ (297,261)	$ 51,291
Basic profit (loss) per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Basic weighted average shares outstanding	84,304,627	84,304,627	84,304,627	84,134,297

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended	
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:		
Net income (loss)	$ (297,261)	$ 51,291
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization expense	80,185	$ 64,917
Bad debt	2,700	
Changes in:		
Accounts receivable	54,331	$ (3,770)
Inventories	(36,796)	32,948
Prepaid expenses	(20,571)	272
Accounts payable and accrued liabilities	(43,517)	(42,545)
Deferred income	10,622	3,361
Net cash (used) provided by operating activities	(250,307)	106,474
Cash flows from investing activities:		
Acquisition of patents	(32,061)	(23,052)
Tooling and machinery	(13,063)	(11,400)
Net cash used by investing activities	(45,124)	(34,452)
Cash flows from financing activities:		

Payments to bank line	(74,663)	(15,257)
Payments to note payables	(27,318)	$ (68,644)
Proceeds from short term borrowings	300,000	
Proceeds from related parties	500,000	$ 50,000
Payments to related parties	(30,000)	(20,000)
Net cash (used) provided by financing activities	668,019	(53,901)
Effect of exchange rates	26,596	(11,252)
Increase in cash	$ 399,184	6,869
Cash, beginning of period		33,767
Cash, end of period	$ 399,184	40,636
Supplemental disclosure of cash flow information:		
Cash paid for interest	$ 2,420	$ 8,046
Cash paid for federal income taxes		

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	9 Months Ended	
	Jun. 30, 2016	Jun. 30, 2015
Statements of Comprehensive Loss [Abstract]		
Net loss	$ (297,261)	$ 51,291
Other comprehensive income (loss)		
Foreign currency translation adjustment	36,319	36,200
Net comprehensive income (loss)	$ (260,942)	$ 87,491

Basis of Presentation	9 Months Ended Jun. 30, 2016
Basis of Presentation [Abstract]	
Basis of Presentation	

Note 1 – Basis of Presentation

Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. ("MIT" or the "Company") and its subsidiary (collectively referred to as the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2015.

In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine month periods ended June 30, 2016 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Going concern

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

Inventories	9 Months Ended Jun. 30, 2016
Inventories [Abstract]	
Inventories	

Note 2 – Inventories

Inventories at June 30, 2016 and September 30, 2015 consist of the following:

Raw materials	
Work in process	
Finished goods	
Total	

Property and Equipment	9 Months Ended Jun. 30, 2016
Property and Equipment [Abstract]	
Property and Equipment	

Note 3 – Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine months ended June 30, 2016 and 2015 was $58,308 and $47,674, respectively.

Intangible Assets	9 Months Ended Jun. 30, 2016
Intangible Assets [Abstract]	
Intangible Assets	

Note 4 – Intangible Assets

As of June 30, 2016 the Company has net patents on certain technologies aggregating $64,915. Amortization expense for the nine months ended June 30, 2016 and 2015 were $21,877 and $17,243, respectively. During the nine months ended June 30, 2016, the Company capitalized patent costs on its needle-free injector of $32,061. Following is a detail of patents at June 30, 2016.

	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)
Patents	$ 145,848	$ 80,933	$ 64,915	7.5 through 15

Joint venture agreement	9 Months Ended Jun. 30, 2016
Joint venture agreement [Abstract]	
Joint venture agreement	

Note 5 – Joint venture agreement

On May 6, 2009, the Company entered into a certain joint venture agreement (the "Joint Venture Agreement") with Jiangsu Hualan Biotechnology Ltd. (China) ("Jiangsu Hualan"). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. ("MIT China" or the "Joint Venture"), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to $2,000,000, and the registered capital shall amount to $1,400,000. The Company invested cash of $426,678 and transferred the license rights to produce and sell the Company's needle-free injectors products into the Joint Venture. The license rights were valued at $280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of $714,000, and owns 51% of the registered capital.

Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party's investment in the registered capital.

In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.

The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of June 30, 2016 and September 30, 2015, the Company's had no recorded investment remaining in the MIT China.

During the nine and three months ended June 30, 2016, the Company had $95,610 and $0 in sales of products to the joint venture. As of June 30, 2016 and September 30, 2015, the Company had a receivable from the joint venture of $32,390 and $51,165, respectively.

During the nine and three months ended June 30, 2015, the Company had approximately $193,000 and $62,000 in sales of products to the joint venture.

As of June 30, 2016 and September 30, 2015, the Company had an advance from the joint venture of $500,000 and $0, respectively. The advance bears no interest and has no formal payment terms.

Bank Line	9 Months Ended Jun. 30, 2016
Bank Line [Abstract]	
Bank Line	**Note 6 – Bank Line** The Company, through a hypothec agreement, has a line of credit up to a maximum of $100,000. The line is secured by Investissement Quebec (a Quebec government entity) and by Karim Menassa (personally) and by account receivables, inventories, equipment and all other assets of the Company. The line bears interest at the prime rate plus 2.5% (5.75% at September 30, 2015). At June 30, 2016 and September 30, 2015, the Company had $0 and $74,663 outstanding under the agreement.

Related Party Transactions	9 Months Ended Jun. 30, 2016
Related Party Transactions [Abstract]	
Related Party Transactions	**Note 7 – Related Party Transactions** Related party balances consist of the following at June 30, 2016 and September 30, 2015: Payable to 9211-0766 Quebec Inc – 8% interest, due December 31, 2015 Advance from MIT China – no interest, no maturity date During the nine and three months ended June 30, 2016, the Company paid approximately $167,000 and $60,000 to a company owned by the President and CEO for consulting fees. During the nine and three months ended June 30, 2015, the Company paid approximately $68,700 and $12,400 to a company owned by the President and CEO for consulting fees.

Stockholders' Equity (Deficit)	9 Months Ended Jun. 30, 2016
Stockholders' Equity (Deficit) [Abstract]	
Stockholders' Equity (Deficit)	**Note 8 – Stockholders' Equity (Deficit)** **Issuance of Common Stock** From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings. For the nine months ended June 30, 2016, there was no common stock issuance. **Preferred Stock** As of June 30, 2016, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval. **Outstanding Options** As of June 30, 2016 and 2015, there are no options outstanding to purchase shares of the Company's common stock. **Outstanding Warrants** There are no outstanding warrants

Operating Leases	9 Months Ended Jun. 30, 2016
Operating Leases [Abstract]	
Operating Leases	**Note 9 –Operating Leases** The Company leases its office and warehouse space under an operating lease that expires on December 31, 2021. The lease calls for a monthly rent of $3,600 (CND).Rent expense for the nine month ended June 30, Future minimum lease commitments pertaining to the lease expire as follow: Year ended: June 30, 2017 June 30, 2018 June 30, 2019 June 30, 2020 June 30, 2021

Debt	9 Months Ended Jun. 30, 2016
Debt [Abstract]	
Debt	**Note 10 – Debt** Debt consists of the following at June 30, 2016 and September 30, 2015: Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016. Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of $5,035 (CND) through May 2016. Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity Total long-term debt (all current)

Contingencies	9 Months Ended Jun. 30, 2016
Contingencies [Abstract]	
Contingencies	**Note 11 – Contingencies** **Legal Proceedings** We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Inventories (Tables)	9 Months Ended Jun. 30, 2016
Inventories [Abstract]	
Schedule of inventories	Raw materials Work in process Finished goods Total

Intangible Assets (Tables)	9 Months Ended
	Jun. 30, 2016
Intangible Assets [Abstract]	
Summary of patents	

	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)
Patents	$ 145,848	$ 80,933	$ 64,915	7.5 through 15

Related Party Transactions (Tables)	9 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]	
Schedule of related party transactions	

Payable to 9211-0766 Quebec Inc – 8% interest, due December 31, 2015
Advance from MIT China – no interest, no maturity date

Operating Leases (Tables)	9 Months Ended
	Jun. 30, 2016
Operating Leases [Abstract]	
Schedule of future minimum lease commitments	Year ended:

June 30, 2017
June 30, 2018
June 30, 2019
June 30, 2020
June 30, 2021

Debt (Tables)	9 Months Ended
	Jun. 30, 2016
Debt [Abstract]	
Schedule of long-term debt	

Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of $5,035 (CND) through May 2016.
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date
Total debt (all current)

Inventories (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Components of inventories		
Raw materials	$ 149,810	$ 136,842
Work in process	67,293	51,511
Finished goods	30,272	22,226
Total	$ 247,375	$ 210,579

Property and Equipment (Details) - USD ($)	9 Months Ended	
	Jun. 30, 2016	Jun. 30, 2015
Property And Equipment (Textual)		
Property and equipment estimated useful lives	The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years.	
Depreciation expense	$ 58,308	$ 47,674

Intangible Assets (Details) - USD ($)	9 Months Ended	
	Jun. 30, 2016	Sep. 30, 2015
Detail of patents		
Accumulated amortization	$ 80,933	$ 56,993
Net Intangible Assets	64,915	$ 53,041
Patents [Member]		
Detail of patents		
Gross Intangible Assets	145,848	
Accumulated amortization	80,933	
Net Intangible Assets	$ 64,915	
Patents [Member] | Maximum [Member]		
Detail of patents		
Weighted Average Life (Years)	15 years	
Patents [Member] | Minimum [Member]		
Detail of patents		
Weighted Average Life (Years)	7 years 6 months	

Intangible Assets (Details Textual) - USD ($)	9 Months Ended		
	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2015
Intangible Assets (Textual)			
Aggregate net patents	$ 64,915		$ 53,041
Amortization expenses	21,877	$ 17,243	
Capitalized patent costs on needle-free injector	$ 32,061		

Joint venture agreement (Details)		1 Months Ended	3 Months Ended		9 Months Ended			
	May. 06, 2009 USD ($) Members	Mar. 31, 2012 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2015 USD ($)	Mar. 31, 2012 CNY (¥)
Joint Venture Agreement (Textual)								
Ownership percentage	49.00%	44.59%						44.59%
Cash invested in joint venture		$ 3,000,000						¥ 18,000,000
Number of members appointed under joint venture agreement | Members	1							
Total investment to be made by joint venture	$ 2,000,000							
Registered capital	1,400,000							
Investment in joint venture	426,678							
Value of license rights	$ 280,000							
Sale of joint venture percentage for an investment by parent company		9.00%						
Sale of products to joint venture, amount			$ 0	$ 62,000	$ 95,610	$ 193,000		
Receivable from the joint venture			32,390		32,390		$ 51,165	
Advance from the joint venture			$ 500,000		$ 500,000		$ 0	
Jiangsu Hualan [Member]								
Joint Venture Agreement (Textual)								
Ownership percentage	51.00%	46.41%						46.41%
Cash invested in joint venture	$ 714,000							
Number of members appointed under joint venture agreement | Members	2							
Taizhou Amazon Investment Center [Member]								
Joint Venture Agreement (Textual)								

Ownership percentage	9.00%	9.00%

Bank Line (Details) - USD ($)	9 Months Ended	
	Jun. 30, 2016	Sep. 30, 2015
Bank Line (Textual)		
Maximum equipment line of credit	$ 100,000	
Amount outstanding	$ 0	$ 74,663
Interest prime rate	2.50%	
Line bears interest rate		5.75%

Related Party Transactions (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Related Party Transactions [Abstract]		
Payable to 9211-0766 Quebec Inc - 8% interest, due December 31, 2015		$ 30,000
Advance from MIT China - no interest, no maturity date	$ 500,000	0
Total	$ 500,000	$ 30,000

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended	
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Related Party Transaction (Textual)				
Interest rate percent	8.00%		8.00%	
CEO [Member]				
Related Party Transaction (Textual)				
Consulting fees	$ 60,000	$ 12,400	$ 167,000	$ 68,700
President [Member]				
Related Party Transaction (Textual)				
Consulting fees	$ 60,000	$ 12,400	$ 167,000	$ 68,700

Operating Leases (Details)	Jun. 30, 2016 USD ($)
Operating Leases [Abstract]	
June 30, 2017	$ 28,000
June 30, 2018	30,000
June 30, 2019	30,000
June 30, 2020	30,000
June 30, 2021	30,000
Operating leases, future minimum payments,Total	$ 148,000

Operating Leases (Details Textual)	9 Months Ended	
	Jun. 30, 2016 USD ($)	Jun. 30, 2016 CAD
Operating Leases (Textual)		
Expiry date of operating lease	Dec. 31, 2021	Dec. 31, 2021
Monthly rent for office and warehouse space		CAD 3,600
Rent expense | $	$ 30,500	

Debt (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Schedule of long-term debt		
Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.	$ 8,477	$ 24,515
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of $5,035 (CND) through May 2016.		$ 11,280
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity	$ 300,000	
Total long-term debt (all current)	$ 8,477	$ 35,795

Debt (Details Textual)	9 Months Ended	12 Months Ended
	Jun. 30, 2016 CAD Numbers	Sep. 30, 2015
Notes payable to bank [Member]		
Debt (Textual)		
Interest rate in addition to prime rate	3.00%	6.25%
Debt maturity date	Dec. 20, 2016	
Canada economic development [Member]		
Debt (Textual)		
Number of consecutive installments for repayment of long-term debt | Numbers	16	
Amount of each installment	CAD 5,035	
Debt maturity date	May 31, 2016	
Due date description of first installment	Sixteen (16) Equal and consecutive quarterly installments	

The rendering log information
Info : In "Consolidated Balance Sheet (Unaudited)", column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.
Info : In "Consolidated Statements of Cash Flows (Unaudited)", column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.
Info : In "Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.